The firm is a healthcare-focused growth equity investor with offices in North America and Europe. The firm manages more than $1B in capital and typically invests $20M–$70M per company over the life of an investment. The firm considers both publicly traded and privately held companies and is open to equity investments and buyout opportunities. The firm primarily targets companies across North America and Europe.
The firm invests across medical technology, biopharmaceuticals, diagnostics, medical devices, life science tools, digital health, and veterinary medicine. The firm is broadly indication-agnostic and places significant emphasis on the clinical utility and health economics of potential investments. The firm primarily seeks later-stage companies with products that are already commercialized or approaching commercialization, favoring opportunities with demonstrated clinical value and clear commercial potential.
From a company and management team perspective, the firm seeks experienced leadership teams willing to work closely with investors to execute growth and commercialization strategies. The firm generally expects to take a board seat and actively participates in strategic decision-making. The firm is flexible regarding transaction structures and evaluates opportunities based on their clinical differentiation, commercial readiness, and potential for long-term value creation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
